Herriot Tabuteau, Chief Executive Officer at Axsome Therapeutics, Inc. (AXSM), sold 159,946 shares at $146.94 ($23.3M) on 2025-12-03, disclosed to the SEC on 2025-12-04.
Scheduled sale ($23.3M) by Chief Executive Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $144.59 | 49,252 | $7.1M | 30.6% |
| 2 | $144.59 | 49,252 | $7.1M | 30.6% |
| 3 | $146.94 | 20,163 | $3.0M | 12.7% |
| 4 | $146.94 | 20,163 | $3.0M | 12.7% |
| 5 | $148.18 | 10,558 | $1.6M | 6.7% |
| 6 | $148.18 | 10,558 |
| $1.6M |
| 6.7% |
| Total | $145.66 avg | 159,946 | $23.3M | 100% |
| Filing → |
| AXSM | SELL | 2026-06-09 | $12.0M | — | Filing → |
| AXSM | SELL | 2026-02-02 | $6.0M | — | Filing → |
| AXSM | SELL | 2026-01-07 | $23.9M | — | Filing → |